Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION
ON REDUCING YOUTH ACCESS
AND APPEAL OF VAPING
PRODUCTS

May 24, 2019
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
[https://policybase.cma.ca/link/policy13933](https://policybase.cma.ca/link/policy13933)

**POLICY TYPE**  
Response to consultation

**DATE**  
2018-10-02

**TOPICS**  
Health care and patient safety  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE  Response to consultation
DATE  2018-09-06
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE       Response to consultation
DATE              2018-08-14
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE: Response to consultation
DATE: 2018-07-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23
TOPICS  Health care and patient safety
         Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Sirs,

The Canadian Medical Association (CMA) recognizes the importance of public health and the potential impact of proposed changes to the regulations governing the sale of cannabis. The CMA welcomes the opportunity to provide comments on the proposed Regulations Amending the Cannabis Act and Regulations Amending the Excise Act, 2001, with respect to cannabis-labelling.

The CMA does not oppose the requirement for a statement regarding the health impacts of cannabis use to be prominently displayed on the package. However, the CMA encourages the federal government to consider a more comprehensive approach to cannabis labelling that includes the following:

1. Clear and prominent labelling of the health risks associated with cannabis use, including the impact on the individual and the wider community.

2. Clear and prominent labelling that provides information on the effects of cannabis use on health, including the potential for addiction, respiratory issues, and mental health impacts.

3. Clear and prominent labelling that promotes the safe and responsible use of cannabis, including information on the appropriate dosage and timing of use.

4. Clear and prominent labelling that provides information on the potential health benefits of cannabis use, where supported by scientific evidence.

The CMA supports the development of a comprehensive approach to cannabis labelling that will contribute to public health goals and promote the responsible use of cannabis.

Yours truly,

[Signature]

[Name]

[Title]

[Organization]
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE        2017-12-07
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

POLICY TYPE
Response to consultation

DATE
2017-11-7

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE        2017-06-28
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE
Response to consultation

DATE
2017-04-05

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada

Response to consultation
2016-10-31
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE Response to consultation
DATE 2016-08-29
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Chief Statement - Application d’États

Express, September 9, 2014 - The CMA’s position is the Task Force on Marijuana’s
tests. Legislation should facilitate the transitioned services. Task Force on 

The CMA is in favor of a well-regulated, accessible, safe and legal cannabis 

The Task Force recommends engaging with the public in a well-organized 

It is important to note that the Task Force on Marijuana’s
communications with respect to the public health and safety of cannabis 

The Task Force recommends that the Public Health Agency of Canada and 

For information, contact: Canadian Medical Association

http://www.cma.ca
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  Response to consultation
DATE  2016-08-12
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE             Response to consultation
DATE                   2016-03-19
TOPICS                 Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Response:
Consultation on the Prescription
Drug List: Naloxone

Health Canada - Prescription Drug Stakes Committee

March 19, 2016
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

**POLICY TYPE**
Response to consultation

**DATE**
2016-01-20

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

**Documents**
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE Response to consultation
DATE 2014-08-26
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents